Comparison · NCT04908189-5563d502
Deucravacitinib vs Placebo: Number of Participants Meeting Dactylitis Resolution at Week 16
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Deucravacitinib vs Placebo: Number of Participants Meeting Dactylitis Resolution at Week 16. Trial comparisons, record NCT04908189-5563d502. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04908189-5563d502
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.551 | 0.441 | 0.657 | wilson | |
| Risk in group 2 | 0.45 | 0.346 | 0.559 | wilson | |
| Risk difference, group 1 minus group 2 | 0.101 | -0.0536 | 0.249 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.23 | 0.895 | 1.68 | log | |
| Odds ratio, group 1 over group 2 | 1.5 | 0.802 | 2.81 | log | |
| Number needed to treat, for one more participant with the outcome on Deucravacitinib than on Placebo | 9.87 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Deucravacitinib | Deucravacitinib 6 mg daily | 43 | 78 | OG000 |
| Group 2 | Placebo | Placebo daily | 36 | 80 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants Meeting Dactylitis Resolution at Week 16
- Description
Number of participants meeting dactylitis resolution at Week 16 among the participants with dactylitis at baseline, where resolution is defined as a tender dactylitis count of 0 in participants with a tender dactylitis count ≥ 1 at baseline. The number of digits in hands and feet with dactylitis will be counted by a blinded assessor.
- Time frame
- Week 16
- Population
- All randomized participants of deucravacitinib and placebo as pre-specified in protocol with tender dactylitis count \>=1 at baseline
Source ClinicalTrials.gov
Trial
- Title
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment
- NCT number
- NCT04908189
- Phases
- PHASE3
- Conditions
- Psoriatic Arthritis
- Interventions
- Deucravacitinib, Placebo, Apremilast
- Lead sponsor
- Bristol-Myers Squibb
- Results first posted
- 2025-04-13
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04908189?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04908189-5563d502